Login / Signup

The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.

Masanori AtsukawaAkihito TsubotaHidenori ToyodaKoichi TakaguchiMakoto NakamutaTsunamasa WatanabeKojiro MichitakaTadashi IkegamiAkito NozakiHaruki UojimaShinya FukunishiTakuya GendaHiroshi AbeNaoki HottaKunihiko TsujiChikara OgawaYoshihiko TachiToshihide ShimaNoritomo ShimadaChisa KondoTakehiro AkahaneYoshio AizawaYasuhito TanakaTakashi KumadaKatsuhiko Iwakiri
Published in: Alimentary pharmacology & therapeutics (2019)
Glecaprevir/pibrentasvir was highly effective and safe in chronic hepatitis C patients with severe renal impairment. Haemodialysis was associated with increased incidence of pruritus, which was the most frequent adverse event, but had little or no influence on the drug concentrations, which indicated that their dialysability is very low and that no dose modification is required in patients undergoing haemodialysis. (UMIN registration no. 000032073).
Keyphrases
  • patients undergoing
  • early onset
  • peritoneal dialysis
  • end stage renal disease
  • drug induced
  • risk factors
  • chronic kidney disease
  • emergency department
  • atopic dermatitis
  • electronic health record